Information Provided By:
Fly News Breaks for December 24, 2019
RHHBY, SRPT
Dec 24, 2019 | 06:00 EDT
The terms of Sarepta Therapeutics' (SRPT) licensing deal with Roche (RHHBY) suggest that Duchenne muscular dystrophy gene therapy is worth at least $6.5B to Sarepta stock, or at least $90 per share, Bernstein analyst Vincent Chen tells investors in a research note. The analyst's math indicates that the expected value of Roche's payments to Sarepta for its DMD gene therapy outside the U.S., after accounting for probability of success, is likely at least $3B, "most likely more," and the expected value of the U.S. DMD gene therapy is likely at least $3.6B, Chen says. Added together, this means the DMD gene therapy should be worth at least $6.5B to Sarepta's stock, "or at least $90 per share, likely well in excess of that," the analyst adds. Shares of Sarepta closed yesterday up $9.41 to $135.58.
News For SRPT;RHHBY From the Last 2 Days
RHHBY
Dec 3, 2021 | 10:16 EST
The Food and Drug Administration announced the approval of Rituxan in combination with chemotherapy for pediatric patients with previously untreated, advanced stage, CD20-positive diffuse large B-cell lymphoma, Burkitt lymphoma, Burkitt-like lymphoma or mature B-cell acute leukemia. Reference Link
RHHBY
Dec 3, 2021 | 07:34 EST
Roche and TIB Molbiol, a newly acquired subsidiary within the Roche Diagnostics division, have added three additional Research Use Only, or RUO, test kits for the detection of mutations present in the novel B.1.1.529 Omicron SARS-CoV-2 variant: VirSNip SARS Spike ins214EPE, VirSNiP SARS-CoV-2 Spike S371L S373P, and VirSNip SARS Spike E484A, the company announced. "The COVID-19 pandemic continues to be an evolving and complex situation, and Roche is committed to responding to healthcare's biggest challenges. The teams at TIB Molbiol have worked around the clock since the new variant emerged, and today we are able to offer a test that can specifically identify the novel B.1.1.529 Omicron SARS-CoV-2 variant to help better understand its spread and behaviour. There is still much to learn about Omicron. It's critical to identify Omicron quickly and accurately, which will help inform ongoing research - including the further development of therapeutics and vaccines - and potentially stop or slow down the advance of this new variant," said Thomas Schinecker, CEO Roche Diagnostics.